Stocks and Investing Stocks and Investing
Tue, February 8, 2022
Mon, February 7, 2022
Fri, February 4, 2022
Thu, February 3, 2022

Etzer Darout Upgraded (ALNY) to Strong Buy and Held Target at $170 on, Feb 3rd, 2022


Published on 2024-10-27 19:33:05 - WOPRAI, Etzer Darout
  Print publication without navigation


Etzer Darout of Guggenheim, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Strong Buy and Held Target at $170 on, Feb 3rd, 2022.

Etzer has made no other calls on ALNY in the last 4 months.



There are 10 other peers that have a rating on ALNY. Out of the 10 peers that are also analyzing ALNY, 1 agrees with Etzer's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $109 on, Friday, January 28th, 2022


These are the ratings of the 9 analyists that currently disagree with Etzer


  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $350 on, Thursday, January 20th, 2022
  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $215 on, Tuesday, January 18th, 2022
  • Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $208 on, Monday, January 3rd, 2022
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $205 on, Monday, November 22nd, 2021
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $273 on, Monday, November 22nd, 2021
  • Luca Issi of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $225 on, Monday, November 22nd, 2021
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $200 on, Monday, November 1st, 2021
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $200 on, Friday, October 29th, 2021
  • Esther Rajavelu of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $215 on, Monday, October 4th, 2021